Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.O)

VRTX.O on Nasdaq

117.80USD
24 May 2017
Change (% chg)

-- (--)
Prev Close
$117.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,810,684
52-wk High
$121.96
52-wk Low
$71.46

Latest Key Developments (Source: Significant Developments)

Vertex Pharma says target review date of Sept. 30 set for FDA's decision on application
Tuesday, 31 May 2016 07:58am EDT 

Vertex Pharmaceuticals Inc : Target review date of september 30, 2016 set for fda's decision on application .u.s. Fda accepts for priority review supplemental new drug application for the use of orkambi® (lumacaftor/ivacaftor) in children with cystic fibrosis ages 6 to 11 who have two copies of the f508del mutation.  Full Article

Spero Therapeutics to acquire worldwide rights to Vertex's VXC-486/VXC-100
Wednesday, 25 May 2016 08:00am EDT 

Spero Therapeutics LLC : Has entered into an agreement with Vertex Pharmaceuticals . Deal to acquire worldwide rights to VXC-486/VXC-100 and a portfolio of innovative antibacterial compounds . Under terms of agreement, Spero will make an upfront payment to Vertex for portfolio rights . Under terms of agreement, Spero will assume responsibility for drug development and bringing compounds to market .Vertex will be eligible to get future devpt,commercial milestones, royalties on any therapeutic products resulting from agreement.  Full Article

Vertex receives Australian approval for Orkambi
Tuesday, 8 Mar 2016 03:50pm EST 

Vertex Pharmaceuticals Inc:Receives Australian approval for Orkambi® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the f508del mutation.Says Therapeutic Goods Administration (TGA) of Australia has approved Orkamb.  Full Article

Vertex Pharmaceuticals Inc and CRISPR Therapeutics establish collaboration to use CRISPR-Cas9 gene editing technology to discover and develop new treatments for genetic diseases
Monday, 26 Oct 2015 08:00am EDT 

Vertex Pharmaceuticals Inc:Says Co and CRISPR therapeutics establish collaboration to use crispr-cas9 gene editing technology.Says will pay future milestones of up to $420 million as well as royalty payments on future sales.Says will pay CRISPR $75 million in cash as part of its up-front commitment.Says companies establish four-year research collaboration and CRISPR to receive $105 million up-front payment.Says will also provide a $30 million investment in CRISPR, which is a private company.CRISPR is also eligible to receive future development, regulatory and sales milestones and royalty payments on future sales.Says Vertex and CRISPR will jointly use the CRISPR-cas9 technology to discover and develop potential new treatments.Says discovery activities will be conducted primarily by CRISPR, and the related expenses will be fully funded by Vertex.Says discovery activities will be conducted primarily by CRISPR, and the related expenses will be fully funded by Vertex.  Full Article

Vertex Pharmaceuticals Inc announces progress in development efforts to treat the cause of cystic fibrosis in the vast majority of people with disease
Thursday, 8 Oct 2015 09:00am EDT 

VertexVertex Pharmaceuticals Inc:Announces significant progress in its development efforts to treat the cause of cystic fibrosis in the vast majority of people with the disease.Says is advancing two next-generation correctors from its research program into clinical development.Plans to initiate phase 2 studies in people with cf evaluating vx-440 or vx-152 in combination with vx-661/ivacaftor in second half of 2016.Says studies of a triple combination planned for the second half of 2016.  Full Article

Vertex Pharmaceuticals Inc receives CHMP Positive Opinions for ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) in the European Union
Friday, 25 Sep 2015 07:17am EDT 

Vertex Pharmaceuticals Inc:Receives CHMP Positive Opinions for ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) in the European Union.CHMP recommends Marketing Authorization for lumacaftor in combination with ivacaftor for people with cystic fibrosis ages 12 and older with two copies of the F508del mutation.CHMP recommends Marketing Authorization for ivacaftor for children with cystic fibrosis ages 2 to 5 with 9 gating mutations & for people with cystic fibrosis ages 18 and older with the R117H mutation.European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive Opinion recommending Marketing Authorization of ORKAMBI.  Full Article

More From Around the Web

BRIEF-Concert pharmaceuticals announces shareholder approval of CTP-656 asset purchase agreement with Vertex Pharmaceuticals

* Concert pharmaceuticals announces shareholder approval of CTP-656 asset purchase agreement with Vertex Pharmaceuticals